Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial

Autor: Teresa Michi, Chiara Mattana, Luca S. Menga, Maria Grazia Bocci, Melania Cesarano, Tommaso Rosà, Maria Rosaria Gualano, Jonathan Montomoli, Savino Spadaro, Matteo Tosato, Elisabetta Rota, Francesco Landi, Salvatore L. Cutuli, Eloisa S. Tanzarella, Gabriele Pintaudi, Edoardo Piervincenzi, Giuseppe Bello, Tommaso Tonetti, Paola Rucci, Gennaro De Pascale, Salvatore M. Maggiore, Domenico Luca Grieco, Giorgio Conti, Massimo Antonelli, for the Gemelli COVID-ICU study group
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal of Intensive Care, Vol 11, Iss 1, Pp 1-14 (2023)
Druh dokumentu: article
ISSN: 2052-0492
DOI: 10.1186/s40560-023-00669-0
Popis: Abstract Background Long-term outcomes of patients treated with helmet noninvasive ventilation (NIV) are unknown: safety concerns regarding the risk of patient self-inflicted lung injury and delayed intubation exist when NIV is applied in hypoxemic patients. We assessed the 6-month outcome of patients who received helmet NIV or high-flow nasal oxygen for COVID-19 hypoxemic respiratory failure. Methods In this prespecified analysis of a randomized trial of helmet NIV versus high-flow nasal oxygen (HENIVOT), clinical status, physical performance (6-min-walking-test and 30-s chair stand test), respiratory function and quality of life (EuroQoL five dimensions five levels questionnaire, EuroQoL VAS, SF36 and Post-Traumatic Stress Disorder Checklist for the DSM) were evaluated 6 months after the enrollment. Results Among 80 patients who were alive, 71 (89%) completed the follow-up: 35 had received helmet NIV, 36 high-flow oxygen. There was no inter-group difference in any item concerning vital signs (N = 4), physical performance (N = 18), respiratory function (N = 27), quality of life (N = 21) and laboratory tests (N = 15). Arthralgia was significantly lower in the helmet group (16% vs. 55%, p = 0.002). Fifty-two percent of patients in helmet group vs. 63% of patients in high-flow group had diffusing capacity of the lungs for carbon monoxide
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje